Princeton, United States
Sonnet BioTherapeutics, founded in 2011 and trading on NASDAQ under (NASDAQ: SONN), is advancing the field of immune therapeutics with its proprietary FHAB™ technology. This platform utilizes a fully human single chain antibody fragment that binds to human serum albumin, improving the delivery and efficacy of therapeutic drugs.
Currently, Sonnet is progressing five cytokine-derived therapeutic candidates, with the lead compound SON-1010 in Phase 1, and SON-080 in Phase 1b/2a development. Their FHAB™ platform has shown significant preclinical promise, offering a tenfold increase in half-life and over a thirtyfold boost in efficacy compared to non-FHAB treatments. This technological edge suggests substantial potential for creating a robust immune oncology pipeline.
Despite the absence of publicized recent investments or stated headquarters, Sonnet BioTherapeutics positions itself as a promising player in biopharmaceutical innovation, with applications extending beyond oncology to various human diseases.
